94 related articles for article (PubMed ID: 26077273)
1. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.
Wang LS; Shaikh T; Handorf EA; Hoffman JP; Cohen SJ; Meyer JE
Pract Radiat Oncol; 2015; 5(5):e457-e463. PubMed ID: 26077273
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
Wo JY; Niemierko A; Ryan DP; Blaszkowsky LS; Clark JW; Kwak EL; Lillemoe KD; Drapek LN; Zhu AX; Allen JN; Faris JE; Murphy JE; Nipp R; Fernandez-Del Castillo C; Ferrone CR; Hong TS
Am J Clin Oncol; 2018 Jul; 41(7):656-661. PubMed ID: 28134673
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
[TBL] [Abstract][Full Text] [Related]
5. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study.
Xu L; Cai S; Xiao T; Chen Y; Qiu H; Wu B; Lin G; Sun X; Lu J; Zhou W; Xiao Y
Colorectal Dis; 2017 Jul; 19(7):O263-O271. PubMed ID: 28603932
[TBL] [Abstract][Full Text] [Related]
10. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.
Krishnan S; Chadha AS; Suh Y; Chen HC; Rao A; Das P; Minsky BD; Mahmood U; Delclos ME; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):755-65. PubMed ID: 26972648
[TBL] [Abstract][Full Text] [Related]
11. Role of neoadjuvant concurrent chemoradiation in locally advanced unresectable pancreatic cancer: a feasibility study at tertiary care centre.
Kapoor R; Khosla D; Gupta R; Bahl A; Shukla AK; Sharma SC
Indian J Cancer; 2014; 51(2):176-9. PubMed ID: 25104204
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma.
Zhang E; Wang L; Shaikh T; Handorf E; Wong JK; Hoffman JP; Reddy S; Cooper HS; Cohen SJ; Dotan E; Meyer JE
Ann Surg Oncol; 2022 Jan; 29(1):354-363. PubMed ID: 34114181
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
[TBL] [Abstract][Full Text] [Related]
16. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting.
Murphy CC; Hofstetter WL; Correa AM; Ajani JA; Komaki RU; Swisher SG
Dis Esophagus; 2013; 26(7):708-15. PubMed ID: 23350713
[TBL] [Abstract][Full Text] [Related]
17. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiation for resected pancreatic adenocarcinoma with or without intraoperative radiation therapy boost: Long-term outcomes.
Calvo FA; Sole CV; Atahualpa F; Lozano MA; Gomez-Espi M; Calin A; García-Alfonso P; Gonzalez-Bayon L; Herranz R; García-Sabrido JL
Pancreatology; 2013; 13(6):576-82. PubMed ID: 24280572
[TBL] [Abstract][Full Text] [Related]
19. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study.
Del Puerto-Nevado L; Marin-Arango JP; Fernandez-Aceñero MJ; Arroyo-Manzano D; Martinez-Useros J; Borrero-Palacios A; Rodriguez-Remirez M; Cebrian A; Gomez Del Pulgar T; Cruz-Ramos M; Carames C; Lopez-Botet B; Garcia-Foncillas J
BMC Cancer; 2016 Jul; 16():519. PubMed ID: 27456229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
